These results show that FN14 predicted taxane protocol failure in breast cancer patients, suggesting a relationship between FN14 expression and the shortening of BrM-free survival (p = 0.066) in patients treated with taxanes (bottom-left panel). Here, TNFRSF12A is linked to breast cancer.